139 related articles for article (PubMed ID: 36119498)
1. Comprehensive prognostic and immunological analysis of CCT2 in pan-cancer.
Lv W; Shi L; Pan J; Wang S
Front Oncol; 2022; 12():986990. PubMed ID: 36119498
[TBL] [Abstract][Full Text] [Related]
2. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role.
Zhu H; Hu X; Ye Y; Jian Z; Zhong Y; Gu L; Xiong X
Front Genet; 2021; 12():687778. PubMed ID: 34594356
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Clinical Characterization of CCT2 Expression and Prognosis
Liu Q; Qi Y; Kong X; Wang X; Zhang W; Zhai J; Yang Y; Fang Y; Wang J
Front Oncol; 2021; 11():614497. PubMed ID: 33869000
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
6. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
Hu X; Zhu H; Zhang X; He X; Xu X
Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
9. Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker.
Yang Y; Liu Q; Guo X; Yuan Q; Nian S; Kang P; Xu Z; Li L; Ye Y
J Oncol; 2022; 2022():8115474. PubMed ID: 36090896
[TBL] [Abstract][Full Text] [Related]
10. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
11.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
12. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
Zhao Q; Zhang Z; Wu Y
Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
Zhao C; Liu Y; Ju S; Wang X
Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.
Liu JN; Kong XS; Huang T; Wang R; Li W; Chen QF
Front Immunol; 2020; 11():2048. PubMed ID: 33072070
[TBL] [Abstract][Full Text] [Related]
15. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
16. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of PLOD2.
Xu Q; Kong N; Zhao Y; Wu Q; Wang X; Xun X; Gao P
Front Genet; 2022; 13():864655. PubMed ID: 35586565
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma.
Zou Q; Yang ZL; Yuan Y; Li JH; Liang LF; Zeng GX; Chen SL
World J Surg Oncol; 2013 Jun; 11():143. PubMed ID: 23782473
[TBL] [Abstract][Full Text] [Related]
20. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
Front Genet; 2022; 13():927046. PubMed ID: 35937984
[No Abstract] [Full Text] [Related]
[Next] [New Search]